ADHD treatment in Europe follows a similar foundation to treatment in the United States, with medication and behavioral support as the two main pillars, but several key differences shape the experience. European countries generally favor methylphenidate as the first-choice medication, have more limited access to certain stimulants common in the US, and use a different diagnostic classification system. Wait times for diagnosis can also be significantly longer, averaging over 20 months across major European countries.
How Europe Diagnoses ADHD Differently
Most European clinicians use the World Health Organization’s ICD-11 classification system rather than the DSM-5, which is standard in the US. The two systems overlap considerably, but they diverge in important ways. The ICD-11 actually lists more individual symptoms than the DSM-5: 11 inattention symptoms and 11 hyperactivity/impulsivity symptoms, compared to nine in each category for the DSM-5. However, the ICD-11 is less specific about how many symptoms a person needs to qualify for a diagnosis. It states that “several symptoms” must be present, while the DSM-5 sets explicit cutoffs (six symptoms per category for children, five for older teens and adults).
In practice, this means European clinicians have somewhat more discretion in making the diagnosis. The ICD-11 also separates hyperactivity and impulsivity into distinct sub-dimensions, which can affect how a person’s presentation is categorized. Whether you’re assessed under one system or the other, the core question is the same: are inattention, hyperactivity, or impulsivity significantly impairing your daily functioning across multiple settings?
Medication: What’s Available and What Isn’t
Methylphenidate is the recommended first-line medication for both children and adults with ADHD across European guidelines, valued for its long track record of efficacy and safety data. This is the same active ingredient found in brands like Ritalin and Concerta. While methylphenidate is also widely used in the US, American prescribers have broader flexibility to start with other stimulants, including mixed amphetamine salts (the active ingredients in Adderall). Mixed amphetamine salts are not widely licensed in European countries, which is one of the most notable differences for anyone comparing the two systems.
Lisdexamfetamine (marketed as Elvanse or Vyvanse depending on the country) is available in many European nations and is typically used when methylphenidate doesn’t work well enough or causes side effects. For non-stimulant options, the European Medicines Agency has approved guanfacine for children and adolescents aged 6 to 17 specifically when stimulants are not suitable, not tolerated, or have proven ineffective. Atomoxetine, another non-stimulant, is also available across much of Europe.
The practical takeaway: if you’re moving to Europe from the US and currently take a mixed amphetamine salt product, you will likely need to switch medications. A European clinician can help identify the closest available alternative.
Behavioral and Non-Drug Treatments
European guidelines generally recommend trying behavioral approaches alongside or before medication, particularly for younger children with milder symptoms. In practice, what this looks like varies widely by country and by the age of the patient. Parent training programs, psychoeducation, and cognitive behavioral therapy are commonly offered.
The evidence base for non-drug treatments is more nuanced than many people expect. A large meta-analysis by the European ADHD Guidelines Group, covering 54 randomized controlled trials, found that behavioral interventions, neurofeedback, cognitive training, and restricted elimination diets did not significantly reduce core ADHD symptoms when assessed by evaluators who didn’t know which treatment the participant received. This “blinded assessment” standard is important because unblinded raters (often parents who know their child is receiving treatment) tend to report larger improvements.
Two nutritional approaches did show some measurable effects. Omega-3 fatty acid supplements produced small but statistically significant reductions in ADHD symptoms even under blinded conditions, though whether those improvements are large enough to matter in daily life remains unclear. Excluding artificial food colorings produced larger effects, but primarily in children who had already been identified as sensitive to those additives. These findings don’t mean behavioral therapy is useless. It helps with organization, emotional regulation, and coping skills that medication alone doesn’t address. But European researchers have been notably honest that the evidence for non-drug treatments reducing the core symptoms of inattention and hyperactivity is limited.
Rising Medication Use Across Europe
ADHD medication use has climbed sharply across Europe over the past decade. A large study analyzing health records from Belgium, Germany, the Netherlands, Spain, and the UK, covering more than 198,000 people between 2010 and 2023, found that medication use increased in every country studied. In the UK, overall ADHD medication prevalence more than tripled. In the Netherlands, it more than doubled.
The most dramatic growth has been among adults over 25, reflecting a broader recognition that ADHD doesn’t simply disappear in adulthood. In the UK, medication use among women in this age group rose more than twentyfold, and among men it increased fifteenfold. These numbers partly reflect genuinely rising diagnosis rates and partly reflect decades of underdiagnosis finally being corrected, particularly in women.
Long Wait Times for Assessment
One of the biggest practical challenges for anyone seeking an ADHD diagnosis in Europe is the wait. Across the UK, France, Germany, Italy, the Netherlands, and Spain, the average time from referral to ADHD diagnosis is 20.4 months. That’s nearly two years. The UK has the longest waits at an average of 31.8 months (almost three years), while Spain has the shortest at 12.2 months.
These delays are driven by a shortage of specialists, growing demand as awareness increases, and the structure of publicly funded healthcare systems where referrals must move through gatekeepers. Many people in countries with long public wait times seek private assessment, which can cut the timeline to weeks but comes with significant out-of-pocket costs. If you’re navigating this process, asking your GP about both public and private pathways early can help you make an informed decision about timing.
Transitioning From Child to Adult Services
One area where European ADHD care has well-documented gaps is the transition from pediatric to adult mental health services, which typically happens around age 18. Clinical guidelines recommend that preparation for this transition should begin in early adolescence, giving young people time to develop self-management skills and build familiarity with what adult services look like. The ideal process involves joint working between child and adult teams, information transfer, and continuity of care.
In practice, many young adults fall through the cracks. Research has found that children’s services often make little distinction in their approach to younger children versus adolescents, with poor awareness of what adult ADHD services actually exist. Some young people disengage from treatment before they ever reach the transition point, simply because no one raises the topic. Guidelines recommend reassessment at the point of transition as part of planning, ensuring the diagnosis is up to date and the treatment plan still fits. For adults, the recommended care pathway includes diagnostic services, medication monitoring and adjustment, and psychoeducation about managing ADHD independently.
Traveling With ADHD Medication in Europe
Because stimulant medications are classified as controlled substances across Europe, traveling between countries with your prescription requires some planning. Within the UK, for example, you can carry up to a three-month supply of prescribed controlled medication for personal use when entering the country, as long as it was lawfully prescribed in your home country. Similar rules apply across most EU nations, though specific limits vary.
If you’re a temporary resident, such as a student or someone on a work assignment, you should travel with a small supply (up to three months) and then see a local clinician to obtain further prescriptions. Controlled medications cannot be mailed to you from overseas. Instead, they must be imported through a registered pharmaceutical wholesaler responding to a local pharmacy order. Before any international move or extended trip, check with both your home country’s regulations on exporting controlled substances and the destination country’s import rules to avoid disruptions in your treatment.